Lifespan Extended by 20%, Stock Price Soars 788%

On June 9, 2025, Klotho Neurosciences announced a major breakthrough in anti-aging research. According to recent analyses of clinical and preclinical studies, focusing on the Klotho gene has led to extended lifespan and reduced age-related degeneration across multiple organ systems.

Following the announcement, Klotho’s stock price surged by 787.8% to $1.82 per share.

Klotho

In 1997, Professor Makoto Kuro-O made a groundbreaking discovery showing that Klotho levels in the blood are directly correlated with mammalian lifespan—the lower the Klotho level, the shorter the lifespan.

A study from the Kuro-O Lab demonstrated that mice with genetically overexpressed full-length Klotho lived 30%-40% longer than normal mice. 

Since then, the Klotho protein has drawn widespread attention for its ability to influence key biological pathways related to aging, such as metabolism, inflammation, and tissue repair.

AAV-Klotho Extends Lifespan by 20%

In February 2025, the journal Molecular Therapy published a study led by Joan Roig-Soriano and colleagues. The study found that enhancing Klotho gene expression reduces age-related degeneration across multiple organs, thereby increasing both lifespan and healthspan.

The research team developed an AAV9 vector encoding the secreted form of the Klotho protein (s-KL). In mouse studies, it effectively increased serum s-KL levels, resulting in a 20% extension in lifespan.

Additionally, KL therapy improved physical performance in mice, reduced muscle fibrosis, and enhanced muscle regeneration. It also improved bone microstructure parameters associated with osteoporosis.

Mice treated with s-KL showed increased cellular markers for adult neurogenesis and immune response. Transcriptomic analysis revealed induced phagocytosis and immune cell activity in the aged hippocampus.

Notably, Klotho Neurosciences has obtained exclusive global rights to s-KL from the Autonomous University of Barcelona (UAB) and the Catalan Institution for Research and Advanced Studies (ICREA).

The Company: Klotho Neurosciences

Klotho Neurosciences is a genetic biotechnology company focused on developing cell and gene therapies based on the Klotho gene to treat degenerative and age-related diseases such as ALS, Alzheimer's, and Parkinson's. Professor Makoto Kuro-O serves as the company’s scientific advisor.

The company is currently developing three pipeline programs, all in the preclinical stage. The first candidate, KLTO-202, is expected to submit an IND application in Q4 2025 to begin clinical trials.

Based on the recent study once again validating the Klotho gene's role in extending lifespan and combating aging, Klotho's stock price soared by 788%.